JAK2 inhibitors for myeloproliferative neoplasms: what is next?
P Bose, S Verstovsek - Blood, The Journal of the American …, 2017 - ashpublications.org
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …
New concepts of treatment for patients with myelofibrosis
P Bose, M Alfayez, S Verstovsek - Current treatment options in oncology, 2019 - Springer
Opinion statement Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor
ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. Patients who …
ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. Patients who …
Novel therapies for myelofibrosis
K Pettit, O Odenike - Current hematologic malignancy reports, 2017 - Springer
Abstract Purpose of Review The purpose of the review was to provide a contemporary
update of novel agents and targets under investigation in myelofibrosis in the Janus kinase …
update of novel agents and targets under investigation in myelofibrosis in the Janus kinase …
SOHO State of the Art Updates and Next Questions: Myelofibrosis
K Pettit, S Verstovsek, M Talpaz - Clinical Lymphoma Myeloma and …, 2019 - Elsevier
The discovery of a mutation in the Janus Kinase 2 gene in 2005 spurred significant progress
in the field of myeloproliferative neoplasms. A comprehensive description of genomic factors …
in the field of myeloproliferative neoplasms. A comprehensive description of genomic factors …
Therapy of Myelofibrosis: Where We Are and What Next
S Verstovsek - Clinical Lymphoma, Myeloma and …, 2017 - clinical-lymphoma-myeloma …
Abstract Treatment of myelofibrosis has greatly improved since the approval of the Janus
kinase (JAK) inhibitor ruxolitinib more than 5 years ago. However, it has become clear that …
kinase (JAK) inhibitor ruxolitinib more than 5 years ago. However, it has become clear that …